In the phase III trial (NCT01479244) of NeuVaxTM, a total of 758 patients with operable low HER2 BC were enrolled, and there was no significant difference in disease-free survival (DFS) between the control and experimental arms (p = 0.069) [45]. Here, ERBB2 is linked to breast cancer.